FCH
BMY icon

Freestone Capital Holdings’s Bristol-Myers Squibb BMY Stock Holding History

Freestone Capital Holdings’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.6K Buy
+1,000
New +$58.3K ﹤0.01% 563

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Freestone Capital Holdings's BMY Position: Q1 2026 in Review

Freestone Capital Holdings increased its Bristol-Myers Squibb (BMY) stake by 7.2% in Q1 2026, buying an estimated $41.7K and bringing the position to 10,612 shares worth $644K. The position accounts for 0.02% of the portfolio, ranked #306.

Freestone Capital Holdings first reported a position in BMY in Q3 2017 and has held it in 30 quarters since. The position peaked at $9.09M in Q1 2021. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Freestone Capital Holdings held 10,612 shares of Bristol-Myers Squibb worth $644K as of Q1 2026.
  • Freestone Capital Holdings bought 716 Bristol-Myers Squibb shares in Q1 2026, an estimated $41.7K.
  • Bristol-Myers Squibb made up 0.02% of Freestone Capital Holdings's portfolio in Q1 2026, its #306 holding.
  • Freestone Capital Holdings first reported a position in Bristol-Myers Squibb in Q3 2017 and has held it in 30 quarters since.
  • Freestone Capital Holdings's Bristol-Myers Squibb position peaked at $9.09M in Q1 2021.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Freestone Capital Holdings's 13F filing for Q1 2026, filed 13 May 2026.